HEPALINK

The company was founded in Shenzhen in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms. The company's three business segments collaborate with each other, driven by unmet clinical needs, and are committed to providing high-quality safe and effective drugs and services to patients around the world to protect their health. The main business covers the heparin industry chain, the investment, development and commercialization of biomacromolecule CDMO and innovative drugs, and is committed to bringing high-quality safe and effective drugs and services to patients around the world to protect their health. Key products and services include enoxaparin sodium preparations, heparin sodium and enoxaparin sodium raw materials, and macromolecule drug CDMO services. Corporate honors: It has successively undertaken national science and technology projects such as the National Biotech Industrialization Demonstration Project, the National Torch Program Project, and the National Key Technological Innovation Project, and has made important contributions to the technological progress, industrial upgrading, and improvement of the ability to generate foreign exchange in China's heparin industry. The company has successively won the “National Technological Innovation Outstanding New Product Award”, “Outstanding Contribution Enterprise to the Shenzhen Special Economic Zone”, “Shenzhen's Outstanding Private Enterprise”, and has become a key high-tech enterprise in the country and Shenzhen.